Effectiveness of dutasteride and solifenacin used to treat benign prostatic hyperplasia

This study aimed to investigate the effects of combining dutasteride (Avodart) and solifenacin (Vesicare) on sexual function in men being treated for benign prostatic hyperplasia (BPH). This study found that the combination of dutasteride and solifenacin does not alter sexual function for men with BPH.

People diagnosed with benign prostatic hyperplasia (non-cancerous overgrowth of the prostate; BPH) often experience lower urinary tract symptoms (LUTS). These include dribbling of urine, incomplete emptying of the bladder and nocturia (getting up to urinate during the night). Medications such as dutasteride and solifenacin can be used to treat BPH. However, it is unclear what effect dutasteride and solifenacin administered together has on sexual function. 

A total of 317 men with BPH were included in this study. They were split into three groups. Group A took dutasteride 0.5 mg/day alone. Group B took dutasteride 0.5 mg/day and solifenacin 10 mg/day. Group C took dutasteride 0.5 mg/day and a higher dose of solifenacin of 20 mg/day. Patients were followed up for 6 months. Questionnaires were used to evaluate LUTS and patient sexual function. 

Symptoms like incomplete emptying, intermittency and weak stream improved in all groups. Sexual function was affected equally in all groups. Poor ejaculation was reported by men in all the groups. However, men in group C reported at the end of the study a significantly higher sexual satisfaction rate compared to the beginning of the study and compared to the other 2 groups.at the end of follow-up

This study found that the combination of dutasteride and solifenacin is effective and safe to treat BPH and severe LUTS, without worsening sexual function satisfaction. 

This study only followed patients for six months. This means that it is not a strong level of evidence. A longer study should be carried out to evaluate the long-term effects of this treatment combination.